Inherited metabolic disorders, or IMDs, are a heterogeneous group of rare genetic diseases in which enzymatic defects disrupt the body’s normal biochemical pathways. Individually they are uncommon, but collectively they represent a significant burden of chronic disease in pediatrics, often affecting the nervous system, liver, heart, and skeleton. Because these disorders are multisystemic by nature, patients typically require lifelong surveillance by metabolic specialists. The Ankara team, led by Merve Koç Yekedüz and colleagues, reasoned that if metabolic dysfunction leaves fingerprints anywhere, it should be in the skin—the body’s largest organ and a tissue in constant, visible dialogue with circulating metabolites, hormones, and nutrients.

The researchers systematically reviewed medical records of all 1,012 IMD patients followed at their center over a thirteen-year period, extracting demographic, biochemical, and clinical data for those with documented skin findings. Dermatological manifestations were categorized and analyzed according to IMD subtype, and representative cases were photographed with informed consent, creating a visual atlas of what metabolic disease actually looks like on the skin. The cohort with skin involvement had a median age of 7.7 years, with a slight male predominance of 53.2 percent. Descriptive statistics were then used to map frequency patterns across diagnostic categories, revealing striking differences in how often each metabolic subgroup announced itself through the skin.

The three most skin-active diagnostic groups were aminoacidopathies, which accounted for 22.2 percent of dermatological cases, biotinidase deficiency at 19.4 percent, and lysosomal and peroxisomal storage disorders at 13.1 percent. Aminoacidopathies—conditions such as phenylketonuria, maple syrup urine disease, and hereditary tyrosinemia—arise when the body cannot properly break down particular amino acids, allowing intermediate metabolites to accumulate to toxic levels. Biotinidase deficiency impairs the recycling of biotin, a vitamin cofactor essential to several carboxylase enzymes, and has previously been reported to cause skin rashes and alopecia that resolve dramatically with biotin supplementation. Storage disorders, meanwhile, reflect the progressive accumulation of undegraded substrates inside cellular lysosomes or peroxisomes, with consequences that extend to connective tissue and skin structure.

By far the most common lesion type in the cohort was the eczematous or inflammatory eruption, seen in 66.1 percent of patients with skin involvement. This dominance of nonspecific inflammatory dermatitis is clinically important because it cuts both ways: it means many rashes in metabolic patients will look ordinary, but it also means that persistent, treatment-resistant eczema in a child with developmental delay, seizures, or unexplained biochemical abnormalities should prompt consideration of an underlying metabolic cause. The study also catalogued a remarkable range of more distinctive findings—persistent Mongolian spots, hyperpigmentation, hypopigmentation, hypertrichosis, xanthomas, ichthyosis, total alopecia, nail dystrophies, vascular lesions, structural anomalies such as inverted nipples and lipodystrophy, and reduced skin elasticity.

Several of these signs carry genuine diagnostic weight when interpreted through a metabolic lens. Extensive or persistently located Mongolian spots, for example, have been associated with lysosomal storage diseases in prior pediatric literature, and their presence in an infant with other subtle features can accelerate referral for enzymatic testing. Xanthomas—yellowish lipid deposits in the skin and tendons—point toward disorders of cholesterol metabolism such as homozygous familial hypercholesterolemia or Tangier disease. Ichthyosiform scaling raises the possibility of conditions like Chanarin-Dorfman syndrome, a neutral lipid storage disease that can present with different forms of erythrokeratoderma. Pigmentary changes connect to aminoacidopathies: in phenylketonuria, deficient tyrosine availability for melanin synthesis produces the classic fair hair and pale skin, and animal studies have shown that hypopigmentation can even be reversed by restoring the missing enzymatic function.

Perhaps the most nuanced insight from the Ankara cohort is that not every skin finding reflects the underlying genetic defect. A substantial proportion of dermatological manifestations were secondary to treatment itself—particularly the restrictive diets that form the backbone of therapy for many IMDs. Protein or carbohydrate limitation, essential for preventing toxic metabolite accumulation in conditions like urea cycle disorders and branched-chain organic acidemias, can nonetheless deprive the skin of adequate nutrients and trigger its own cutaneous pathology. The literature describes acrodermatitis dysmetabolica, a painful, eroded rash resembling zinc deficiency, in infants with maple syrup urine disease and phenylketonuria, typically flaring when metabolic control slips. Distinguishing disease-driven from diet-driven skin changes is therefore a practical skill that can directly alter clinical management.

The study’s authors argue that dermatological evaluation should become an integral part of routine care for IMD patients, and the data give that recommendation concrete force. Skin findings can serve as early diagnostic cues—sometimes appearing before neurological or systemic manifestations—and can also function as visible indicators of treatment efficacy, since resolving rashes, regrowing hair, or normalizing pigmentation may signal that biochemical control has been achieved. For a field in which diagnosis often hinges on expensive enzymatic assays and genetic sequencing, a careful physical examination of the skin remains one of the cheapest, fastest, and most accessible diagnostic instruments available. The researchers also documented representative cases photographically, building a visual reference that could help clinicians elsewhere recognize patterns they might otherwise miss.

The work builds on a growing body of literature mapping what has been called the clinical and biochemical footprints of inherited metabolic disease, including a 2021 review of metabolic dermatoses in Molecular Genetics and Metabolism. Prior case reports have linked congenital disorders of glycosylation to wrinkled skin and the so-called hanging fat sign, homocystinuria to pigmentary and vascular changes, prolidase deficiency to chronic lower-extremity ulcers, and mitochondrial dysfunction to a spectrum of dermatologic findings. What the Ankara study adds is scale: rather than isolated case reports, it provides cohort-level frequencies drawn from more than a thousand consecutively followed patients, allowing clinicians for the first time to appreciate how common skin involvement truly is across the IMD spectrum and which diagnostic subgroups are most likely to display it.

For practicing pediatricians and dermatologists, the message is straightforward. One out of four children with an inherited metabolic disorder will show something on their skin, and that something ranges from an ordinary-looking eczema to a highly specific sign like tendon xanthomas or ichthyosis. In a child already known to have an IMD, new skin findings warrant attention as possible markers of disease activity or dietary complications. In a child without a diagnosis, stubborn inflammatory eruptions combined with any systemic red flags should prompt metabolic screening rather than endless cycles of topical steroids. As genomic medicine continues to expand the recognized universe of metabolic disease, the humble skin examination—noninvasive, instantaneous, and free—may prove to be one of the most underused diagnostic tools in modern pediatrics, and this study makes a compelling case for putting it back at the center of the clinical encounter.

Subject of Research: Dermatological manifestations of inherited metabolic disorders in a pediatric cohort

Article Title: Cutaneous clues in inherited metabolic disorders: insights from a single-center cohort

Article References: Koç Yekedüz, M., Eminoğlu, F. T., Sürücü Kara, İ., Akyüzlüer Güneş, M. S., Kütükkiran, İ., & Köse, E. (2026). Cutaneous clues in inherited metabolic disorders: insights from a single-center cohort. Archives of Dermatological Research, 318(1), Article 428. https://doi.org/10.1007/s00403-026-04927-7

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04927-7

Keywords: inherited metabolic disorders, dermatology, skin findings, aminoacidopathies, biotinidase deficiency, lysosomal storage disorders, eczema, hyperpigmentation, ichthyosis, pediatric metabolism, dietary restriction, rare disease

The findings emerge from a series of experiments led by Kerri Conklin, Haley Peters, and John Hatle of the University of North Florida, together with Marshall D. McCue of Sable Systems International. The team set out to test a hypothesis that has been gathering momentum in the aging literature: that shifts in the catabolism of branched-chain amino acids, the trio of leucine, isoleucine, and valine that animals cannot synthesize themselves, are not merely a byproduct of dietary change but a driver of longevity itself. Interest in this question has been sharpened by recent work in mice showing that restricting dietary isoleucine, one of the three branched-chain amino acids, improves metabolic health and extends lifespan in genetically heterogeneous animals. What remained unclear was how such a dietary intervention reshapes the way the whole organism actually processes these amino acids, and whether that processing is what connects the diet to a longer life.

To find out, the researchers turned to an animal model that offers advantages that mice and fruit flies do not. The lubber grasshopper, a large herbivorous insect, can be fed precisely defined synthetic diets, its eggs can be counted with ease across a reproductive season that spans months, and its size makes it possible to measure metabolic events that would be vanishingly difficult to detect in smaller creatures. Adult female grasshoppers were assigned to different diets: a high-quality diet in which the essential amino acids were balanced to match reproductive needs, diets with moderate or severe restriction of isoleucine, and control groups fed lettuce, either with restricted energy or available freely. The freely available lettuce group served a crucial purpose, because it reproduces the classic pattern in which abundant, low-quality food produces high reproduction and short life, the textbook trade-off that the researchers wanted to see whether they could break.

The technical centerpiece of the study was a method for watching amino acid catabolism happen inside a living animal. Rather than inferring catabolic activity from enzyme levels or metabolite concentrations in blood, the team tracked the fate of carbon atoms directly. Grasshoppers were fed amino acids labeled with the stable isotope carbon-13, and the researchers then measured the appearance of carbon-13 in the carbon dioxide exhaled in the animals’ breath using a laser-based analyzer. Because the carbon skeleton of an amino acid can only leave the body as carbon dioxide if it has been fully oxidized through catabolic pathways, the amount of labeled carbon dioxide in the breath provides a direct, organism-level readout of how fast a specific amino acid is being burned. This approach, conceptually related to the indicator amino acid oxidation technique used in human nutrition research, allowed the team to distinguish between the handling of leucine and that of valine, something bulk measurements of amino acid pools cannot do.

The results painted a picture of remarkable specificity. All three of the defined diets, the balanced high-quality diet and the two levels of isoleucine restriction, extended lifespan relative to the freely fed lettuce control. Yet these same diets produced very different reproductive outcomes and very different catabolic profiles. The severely isoleucine-restricted animals and the energy-restricted lettuce group showed the highest rates of leucine catabolism of any animals in the study, but their egg production collapsed. The moderately restricted animals also showed elevated leucine burning, but their reproduction was delayed rather than abolished. The balanced high-quality diet, by contrast, produced an intermediate rate of leucine catabolism while the animals continued laying eggs at a sustained pace. In other words, the dose of leucine oxidation appeared to predict the combination of lifespan and fertility that each group achieved.

Two additional observations strengthened the interpretation. First, the grasshoppers on low-isoleucine diets did not compensate by eating more, which means the effects on catabolism and lifespan cannot be explained as a simple consequence of altered total food intake. Second, valine catabolism, measured with the same isotope-tracing method, did not reach statistical significance but trended in the same direction as leucine, hinting that the pattern may reflect branched-chain amino acid metabolism more broadly rather than a quirk of a single amino acid. The authors summarize the pattern succinctly: weak leucine catabolism is linked to a short lifespan, excessive leucine catabolism is linked to impaired reproduction, and intermediate levels are associated with longevity and sustained reproduction.

Why should the burning of a single amino acid carry such weight? The answer likely lies in the peculiar biochemistry of the branched-chain family. Unlike most amino acids, which are processed primarily in the liver, branched-chain amino acids are broken down largely in peripheral tissues, and their catabolism feeds carbon into the tricarboxylic acid cycle, the central hub of energy metabolism. The first committed step, catalyzed by the branched-chain alpha-ketoacid dehydrogenase complex, is tightly regulated and represents a metabolic decision point: oxidize the amino acid for energy, or divert it toward protein synthesis, including the yolk proteins that fuel egg production. An animal that burns leucine vigorously is, in effect, diverting amino nitrogen and carbon away from reproductive investment and toward somatic maintenance, the classic allocation shift that life-history theory predicts should accompany lifespan extension. The new data suggest that the degree of that shift, not merely its presence or absence, determines whether the animal pays the full reproductive cost of living longer.

The study also resonates with a broader body of work linking branched-chain amino acid metabolism to aging and disease across the tree of life. Elevated circulating branched-chain amino acids are a well-replicated metabolic signature of obesity and insulin resistance in humans, and experiments in mice have shown that reducing consumption of these amino acids can restore metabolic health. In worms, a metabolic signature of long life includes altered branched-chain amino acid handling, and work in fruit flies has examined whether branched-chain amino acids act differently from other essential amino acids in shaping lifespan. There are even links to neurodegeneration and cancer, where branched-chain amino acid catabolism emerges as a modifiable pathway in astrocytes and tumors. What the grasshopper study adds is an organism-level, nutrient-by-nutrient measurement of catabolism in an animal whose reproduction can be tracked continuously, connecting the molecular pathway to whole-animal fitness outcomes in a way few systems allow.

Perhaps the most provocative implication concerns the reproduction-longevity trade-off itself. In the freely fed lettuce control, grasshoppers reproduced heavily and died young, the canonical pattern. Severe isoleucine restriction and energy restriction broke the pattern in the usual way, buying lifespan at the price of fertility. But the balanced high-quality diet, matched to the amino acid composition of the animals’ reproductive needs, appeared to soften the trade-off, sustaining egg output while still extending life, and doing so at an intermediate rate of leucine oxidation. This echoes earlier work from the same group showing that high-quality dietary protein can partially break the lifespan-reproduction trade-off in lubber grasshoppers, and it suggests that the goal for interventions aimed at human aging should not simply be to maximize catabolic flux but to tune it. The metabolic ideal, if the grasshopper data translate, is moderation: enough branched-chain amino acid burning to support maintenance and longevity, not so much that the machinery of reproduction is starved.

Of course, grasshoppers are not people, and the authors are careful to frame their results as associations rather than proof of causation. The study measures catabolism and life-history outcomes together; it does not demonstrate that manipulating leucine oxidation directly extends lifespan. Still, the convergence of evidence from mice, flies, worms, and now an insect with a fundamentally different body plan suggests that branched-chain amino acid catabolism is a conserved regulator of physiological aging, as work in nematodes first proposed. If future experiments can establish causation, perhaps by pharmacologically or genetically tuning the rate of leucine oxidation, the humble grasshopper’s breath may have pointed the way toward a principle for healthy aging that applies far beyond the meadow: longevity favors the metabolically moderate.

Subject of Research: The association between dietary isoleucine restriction, branched-chain amino acid catabolism, longevity, and reproduction in lubber grasshoppers

Article Title: Intermediate leucine catabolism is associated with longevity and sustained reproduction in grasshoppers

Article References: Conklin, K., Peters, H., Tomlinson, M., Sein, R., Kaplan, J., Nealy, G., Horton, A., Husein, H., Ihemis, I., Clark, C., McCue, M. D., & Hatle, J. (2026). Intermediate leucine catabolism is associated with longevity and sustained reproduction in grasshoppers. GeroScience. https://doi.org/10.1007/s11357-026-02476-5

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02476-5

Keywords: isoleucine restriction, branched-chain amino acids, leucine catabolism, lifespan extension, reproduction-longevity trade-off, grasshoppers, carbon-13 isotope tracing, amino acid oxidation, aging, GeroScience, metabolism, dietary restriction

The team assembled lipidomics datasets from mice, the roundworm Caenorhabditis elegans, the fruit fly Drosophila melanogaster and humans, covering multiple tissues and multiple ages. Rather than tracking individual lipid species one by one, they computed a summary statistic: the average acyl chain length of each lipid class, essentially a weighted average of the number of carbon atoms in the fatty acid tails. When they plotted this metric against age, a striking pattern emerged. In lipid class after lipid class, across species and tissues, longer-chain species increased in abundance with age while shorter species declined. The correlation between chain length and age-related fold change was consistently positive, indicating that the lipidome does not merely drift randomly as an animal ages but shifts in a directional, predictable way toward longer fat.

Technical detail matters here, because the shift is not simply a matter of some lipids growing. The authors describe the remodeling as ratiometric: the proportion of long lipids rises largely because shorter, medium-chain species are depleted, changing the ratio between the two pools. Much of the action in the mouse data clustered around a carbon length of eighteen, a pivot point where the balance between shorter and longer species appears to tip with age. This kind of relative remodeling has consequences for membrane physics. Longer saturated chains pack more tightly, increase membrane thickness, and reduce fluidity, which can alter the behavior of embedded proteins, ion channels and transporters. Molecular dynamics simulations performed by the team, using both atomistic CHARMM-based models and coarse-grained Martini 3 models of multi-component plasma membranes, showed that increasing average lipid length changes key biophysical properties of the bilayer, providing a mechanistic rationale for why such a shift might impair cellular function.

The pattern was not confined to healthy aging. In human heart tissue, lipid chain length increased not only with age but also with the progression of heart disease, suggesting that the same remodeling that accompanies growing old is amplified in pathological cardiac remodeling. Conversely, interventions known to slow aging pushed the lipidome in the opposite direction. In mice, dietary restriction shortened cardiac lipids, and treatment with rapamycin, the mTOR-inhibiting drug that reliably extends lifespan in laboratory animals, shifted lipid length downward both in HL-1 mouse cardiac cells in culture and in the hearts of treated mice. The convergence of these observations, that pro-longevity interventions shorten lipids while aging and disease lengthen them, is what transforms the correlation into a plausible causal axis.

To find the machinery behind the remodeling, the researchers turned to genetics. They compiled a list of lipid-remodeling genes and looked for those whose expression tracked lifespan. One enzyme stood out: phospholipase B1, or Plb1, a lipid remodeler that cleaves fatty acids from phospholipids and thereby participates in the Lands cycle, the continuous deacylation and reacylation that keeps membrane composition tuned. Plb1 expression correlated with lifespan in mice, and Mendelian randomization analyses of human genetic data, which use naturally occurring genetic variants as instruments to test causal relationships, supported a role for the gene in human frailty. In C. elegans, the worm orthologue F36A2.9 formed a functional axis with elongase enzymes such as ELO-1 and ELO-3, the fatty acid elongation enzymes that add two-carbon units to growing acyl chains.

The worm experiments delivered the most dramatic result. When the researchers knocked down Plb1/F36A2.9 by RNA interference, the age-related lengthening of the lipidome was reversed, and the animals lived longer. Critically, the lifespan extension depended on lipid length itself: the benefit scaled with how much the intervention shortened lipid chains. Knocking down elongases produced distinct lipidomic and longevity profiles, reinforcing the idea that chain length, rather than some unrelated function of the remodeler, is the relevant variable. The team also supplemented HeLa cells with C21:0, an odd-chain fatty acid, and observed lipidome-wide shifts consistent with the length hypothesis, while the membrane simulations tied the compositional changes to altered bilayer properties and reduced cellular viability when lipids became too long.

What makes the study compelling is its breadth. Lipid chain lengthening appeared in skeletal muscle of aging men and women, in aging hearts, in flies tested in two independent biological replicates, in worms, and across multiple mouse tissues. It connects to earlier observations that had hinted at the link between fat and lifespan: the membrane pacemaker hypothesis, which proposed that membrane fatty acid composition sets the pace of aging; epigenetic clocks that include methylation of the elongase gene ELOVL2 as an age marker; and prior lipidomic surveys in mice and humans that catalogued age-related lipid changes without identifying chain length as the organizing principle. By computing a single interpretable metric across all of these datasets, the new work unifies scattered findings into one coherent signature.

The authors have made the approach accessible. An R script for computing lipid chain length from lipidomics data is freely available on GitHub, and all newly generated datasets, from fly aging replicates to worm RNAi lipidomes and membrane simulation outputs, are published as supplementary tables. This matters because average chain length is a cheap, robust readout that any laboratory with lipidomics data can compute retrospectively. Existing cohorts could be reanalyzed tomorrow to ask whether lipid length predicts disease progression, response to exercise, or mortality, and the study itself includes evidence that short-term exercise interventions in postmenopausal women and sitting-reduction trials modulate the relevant lipid classes.

Important caveats remain before anyone should expect a lipid-shortening pill. The causal evidence in mammals is currently correlational, resting on expression associations and human genetic instruments rather than direct manipulation of Plb1 in mice or people. Worms are distant from humans, and lipid biology is notoriously context-dependent, with chain length interacting with desaturation, headgroup identity and subcellular compartment. The ratiometric nature of the remodeling also means that restoring a youthful lipidome may require replenishing depleted short-chain species, not merely inhibiting elongation, and the consequences of doing so in a living mammal are unknown. Heart disease data show association with progression, not proof that long lipids drive the disease.

Even with those qualifications, the study adds a genuinely new entry to the growing list of aging hallmarks, and one with unusual practical appeal. Lipids are druggable, their chain lengths are set by well-characterized elongases, remodelers and peroxisomal beta-oxidation pathways, and the metric that captures the aging signature is a single number per lipid class. If future work confirms that shortening lipid chains improves healthspan in mammals, the humble fatty acid tail, long treated as a passive structural detail, will have earned a central place in the biology of aging, and the quest to slow it will have acquired an unexpectedly fatty target.

Subject of Research: Age-related elongation of lipid acyl chains as a conserved hallmark of aging and its manipulation to extend lifespan

Article Title: Longer lipids mark aging and constrain lifespan

Article References: Longer lipids mark aging and constrain lifespan. (n.d.). https://doi.org/10.1038/s43587-026-01223-x

Image Credits: AI Generated

DOI: 10.1038/s43587-026-01223-x

Keywords: lipidomics, aging, lipid acyl chain length, Plb1, Caenorhabditis elegans, lifespan extension, membrane biophysics, rapamycin, dietary restriction, elongases, Mendelian randomization, heart disease

The research team, led by Meiling Lai, Fengge Xu, Yingxia Xu, and senior author Yu-Xuan Lyu, assembled a carefully controlled cross-sectional cohort of 80 intact laboratory Beagles ranging from 1 to 11 years of age. Using a single breed kept under controlled laboratory conditions was a deliberate design choice. Pet dogs vary enormously in diet, exercise, neuter status, and environment, all of which can confound measurements of immune aging. By studying intact animals of one breed across a defined age range, the researchers could isolate the effects of age and sex on blood cell counts and circulating inflammatory signals with unusual clarity.

The first major finding is that canine immune aging is neither uniform nor linear. Several absolute leukocyte counts, meaning the numbers of specific white blood cell types circulating in the blood, did not simply decline steadily with age. Instead, they fell during the middle of the lifespan and then rose again in the oldest, geriatric dogs. This kind of undulating, non-linear trajectory echoes what has been described in human aging research, where large-scale studies of the plasma proteome have revealed waves of molecular change rather than a smooth slope. It suggests that the aging immune system passes through distinct stages, and that measurements taken at a single age may miss the bigger picture.

The serum cytokine data, which capture the levels of signaling proteins that immune cells use to communicate, told an even more interesting story when the researchers split the results by sex. More cytokines varied significantly with age in male dogs than in female dogs, pointing to a sex-stratified pattern of immune aging. This mirrors a growing body of human evidence showing that women and men age immunologically in different ways, with differences in immune cell composition, inflammatory tone, and susceptibility to autoimmune and infectious disease. However, the authors were careful to note a statistical caveat: when they formally tested for age-by-sex interactions and corrected for multiple comparisons using false discovery rate methods, those interaction effects did not remain significant. The sex-stratified patterns are therefore suggestive rather than definitive, and the researchers frame them as a basis for future work rather than a settled conclusion.

Why does this matter for human medicine? The concept of inflammaging, the chronic low-grade inflammation that accumulates with age and contributes to cardiovascular disease, frailty, and other conditions, is a central pillar of modern geroscience. If dogs show their own version of inflammaging, and if that process unfolds differently in males and females, then dogs could serve as a powerful translational model for testing interventions aimed at damping down age-related inflammation. The new study provides the reference map that such interventions will need: a description of what normal immune aging looks like in a controlled canine population, stage by stage, sex by sex.

The second half of the study moved from observation to intervention. The team evaluated 24 young Beagles that received one of three geroprotective treatments for 90 days: rapamycin, canagliflozin, or dietary restriction. Rapamycin, a drug that inhibits the mechanistic target of rapamycin pathway, is perhaps the most intensively studied longevity intervention in laboratory animals, having extended lifespan in mice even when administered late in life. Canagliflozin, a diabetes drug belonging to the SGLT2 inhibitor class, has shown lifespan-extending effects in male mice and is being explored for broader geroprotective properties. Dietary restriction, the reduction of caloric intake without malnutrition, remains the most reproducible intervention for slowing aging across species, with classic studies in dogs showing that lifelong moderate restriction extended lifespan and delayed age-related changes.

After the 90-day intervention window, the three treatments produced clearly different immune and metabolic signatures. Rapamycin was associated with the broadest response across the measured cytokine endpoints, suggesting that mTOR modulation produces wide-reaching shifts in inflammatory signaling even over a relatively short period in young animals. Canagliflozin showed a narrower set of cytokine differences, alongside a descriptive reduction in body weight, hinting that its effects on immune aging may be more targeted. Dietary restriction reduced body weight as expected but did not alter any of the measured immune endpoints within the study window. That last result is notable because it separates the metabolic effects of caloric restriction from its immunological effects, at least on the timescale and endpoints examined here.

The authors are appropriately cautious about these intervention findings. The group sizes were small, with only a handful of dogs per treatment arm, and cytokines were measured only at the endpoint of the study rather than before and after treatment. Without baseline measurements, it is impossible to distinguish true treatment-induced changes from pre-existing differences between groups. The researchers explicitly describe the intervention results as exploratory and hypothesis-generating, a framing that reflects good scientific practice but also underscores how early this line of work remains. Larger, longitudinal trials with baseline sampling will be needed to confirm whether rapamycin’s broad cytokine response represents a genuine geroprotective signature or statistical noise amplified by small numbers.

Even so, the study arrives at a moment of rapid growth in canine geroscience. Large initiatives such as the Dog Aging Project are following tens of thousands of companion dogs to identify biological markers of aging, and a major randomized trial called TRIAD is currently testing rapamycin in healthy middle-aged dogs. Previous smaller trials of short-term rapamycin in companion dogs have suggested effects on immune function and heart health. The new Beagle study complements these efforts by offering a controlled, sex-stratified baseline for immune aging and by providing early comparative data on three distinct geroprotective strategies within a single experimental framework. Because dogs develop many of the same chronic diseases humans do, and share our living environments, positive results in canine trials carry more translational weight than rodent findings alone.

The broader lesson from the study is that aging biology cannot be understood without accounting for sex. Sex differences in lifespan are well documented across mammals, and the immune system is one of the most sexually dimorphic organ systems in the body. By showing that canine cytokine profiles age differently in males and females, even if formal statistical interactions await confirmation in larger cohorts, the study adds dogs to the list of species in which immune aging must be studied separately in each sex. For veterinarians, the stage-specific hematologic changes and sex-stratified cytokine patterns could eventually inform better interpretation of blood tests in aging dogs. For geroscientists, the work lays the groundwork for longitudinal studies that track individual animals over time, measure immune markers before and after intervention, and determine whether short-term molecular responses to drugs like rapamycin predict longer-term gains in healthspan and lifespan. The dogs, as so often, may end up teaching us a great deal about ourselves.

Subject of Research: Sex differences in immune aging and geroprotective intervention responses in dogs

Article Title: Sex-stratified immune patterns across the canine lifespan and short-term responses to geroprotective interventions

Article References: Lai, M., Xu, F., Xu, Y., Mironenkov, A., Jin, Y., Zhang, S., Pan, J., Li, M., Deng, B., Zhu, J.-K., & Lyu, Y.-X. (2026). Sex-stratified immune patterns across the canine lifespan and short-term responses to geroprotective interventions. Biogerontology, 27(5), Article 172. https://doi.org/10.1007/s10522-026-10518-w

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10518-w

Keywords: canine aging, immune aging, inflammaging, sex differences, rapamycin, canagliflozin, dietary restriction, geroprotectors, cytokines, Beagle model, geroscience, blood biomarkers

The review, led by joint first authors Robin Quagebeur and Emma De Schuyteneer, followed the PRISMA-ScR reporting guidelines and searched eleven databases for studies of individuals diagnosed with anorexia nervosa or atypical anorexia nervosa. To be included, a study had to examine negative affect, anxiety, or stress and report outcomes connected to eating-disorder symptoms. The team then sorted the resulting literature into four methodological families: retrospective self-report studies, which ask people to recall past experiences; qualitative studies, which capture lived experience in interviews and narratives; experimental studies, which deliberately provoke emotions under controlled conditions; and daily life studies, which use techniques such as ecological momentary assessment to sample feelings and behaviours in real time as people go about their routines. This taxonomy matters because each method answers a slightly different question, and the review shows that the answers do not always converge.

The experimental strand of the literature provides some of the clearest signals. When researchers induce negative emotions in the laboratory, for example by showing distressing films or asking participants to recall painful memories, people with anorexia reliably report intensification of disorder-specific cognitions: thoughts about weight, shape, dietary rules, and the perceived consequences of eating. In other words, the emotional state does not merely coexist with the illness; it appears to amplify the cognitive machinery that sustains it. This aligns with influential theoretical models of eating disorders, including the affect regulation model and the escape from self-awareness account, which propose that disordered eating behaviours function as maladaptive strategies for managing unbearable emotional states. The experimental evidence reviewed here gives those models a firmer empirical footing, at least for the cognitive component of the disorder.

Daily life studies, which capture behaviour where it actually happens, tell a more differentiated story. Across experience-sampling research, momentary negative affect is consistently associated with binge eating and with purging, the behaviours most directly tied to emotional escape and relief. Yet when the outcome is dietary restriction, the hallmark behaviour of the restrictive subtype of anorexia, the associations are mixed, with some studies finding that negative emotions precede restriction and others finding no reliable link or even the opposite pattern. The same inconsistency applies to physical activity, which for many patients becomes a compulsive means of burning calories. This heterogeneity suggests that restriction and compulsive exercise may not serve the same emotional functions across individuals, and that subtype differences, between the binge-purge and restrictive presentations of the illness, may be critical to understanding when emotion actually drives behaviour.

Anxiety emerges in the review as a particularly mealtime-bound phenomenon. Studies that measured anxiety in the moments surrounding eating found that it was often related to caloric intake, with anticipatory anxiety about eating, body concerns, and the social context of meals shaping how much food people consumed. This is a clinically intuitive but empirically important observation: for many individuals with anorexia, the plate itself is a threat cue, and the anxiety it provokes in the moment may directly determine whether a meal is completed, reduced, or avoided altogether. Interventions that target mealtime anxiety, such as supported meals and exposure-based approaches, therefore have a clear mechanistic rationale, and the review’s findings suggest that measuring anxiety at the moment of eating could help clinicians identify which patients need the most intensive support around food.

Stress, the third pillar of the review, proves to be the most methodologically tangled construct. Most studies relied on general stress paradigms, most prominently the Trier Social Stress Test, a standardized laboratory challenge in which participants deliver a speech and perform mental arithmetic before an evaluative panel. The effects of such challenges on eating-disorder behaviours were mixed, and the review highlights a striking divergence between subjective and physiological stress responses: what people reported feeling did not always match what their bodies were doing. Physiological stress is typically indexed through the hypothalamic-pituitary-adrenal axis, measured via the stress hormone cortisol, and through the sympathetic-adrenomedullary system and broader autonomic nervous system activity. Because self-reported stress and biological stress can come apart, studies that rely on only one channel may be systematically missing part of the picture, and the review argues that this dissociation is itself a key finding deserving of targeted research.

One of the review’s most sobering conclusions is how rarely the three constructs have been compared head to head. Negative affect, anxiety, and stress are conceptually overlapping but distinct: negative affect is a broad valence state, anxiety is a specific fear-oriented emotion often with anticipatory character, and stress encompasses both a psychological appraisal and a physiological response. Yet few studies measured more than one of these within the same design, which makes it impossible to say which construct is most tightly coupled to symptoms or whether they act through shared or separate pathways. The authors argue that future work should adopt multi-modal assessments, combining momentary self-reports with physiological monitoring, potentially including wearable sensors, so that the relative contributions of each affective state can be disentangled rather than assumed.

The methodological inconsistencies documented in the review are not trivial. Studies varied in how they conceptualized negative affect, anxiety, and stress, in the instruments they used, in the timing of their measurements, and in the symptom outcomes they reported. Retrospective questionnaires, for instance, are vulnerable to memory bias and to the way eating disorders distort self-perception, whereas ecological momentary assessment reduces recall demands but introduces its own burdens and reactivity. Experimental paradigms offer control but sacrifice ecological validity. The review’s framework, by making these differences explicit, gives the field a map of where its evidence is strong and where it is fragile, and it provides a template for how future studies could be designed to be comparable with one another rather than isolated data points.

For clinicians, the practical message is that emotional states are not background noise in anorexia nervosa; they are moment-to-moment modulators of symptoms. The strongest and most consistent associations involve the emotional amplification of disorder-specific thoughts and the triggering of binge-purge behaviour, while restriction and compulsive exercise follow more idiosyncratic patterns that may require individualized formulation. Timing interventions to moments of peak negative affect, teaching patients to recognize the emotional antecedents of their urges, and addressing mealtime anxiety directly all emerge as evidence-supported priorities. For researchers, the message is equally clear: the next leap in understanding will come from studies that measure mind and body together, in the same moments, in the same individuals, and that directly compare negative affect, anxiety, and stress rather than treating them as interchangeable labels for the same phenomenon.

As a scoping review, the study maps the terrain rather than pooling effect sizes, and the authors are careful about the limits of their conclusions. The translation from feeling to behaviour, they conclude, varies by context and by illness subtype, and the field’s understanding of the interplay between affective states and symptoms in anorexia nervosa will only advance with stronger methodological consistency. But the central insight stands out with unusual clarity for a body of literature this heterogeneous: in the moments when negative emotions, anxiety, and stress rise, the cognitive and behavioural symptoms of anorexia nervosa are close behind. Capturing those moments, in the laboratory and in daily life, may be the key to predicting, and ultimately interrupting, the cycles that keep the illness alive.

Subject of Research: Momentary associations of negative affect, anxiety, and stress with symptoms in anorexia nervosa

Article Title: The momentary associations of negative affect, anxiety and stress with symptoms in individuals with anorexia nervosa: a scoping review

Article References: Quagebeur, R., De Schuyteneer, E., Vergaelen, E., Presseller, E. K., & Vrieze, E. (2026). The momentary associations of negative affect, anxiety and stress with symptoms in individuals with anorexia nervosa: a scoping review. Journal of Eating Disorders. https://doi.org/10.1186/s40337-026-01744-1

Image Credits: AI Generated

DOI: 10.1186/s40337-026-01744-1

Keywords: anorexia nervosa, negative affect, anxiety, stress, eating disorders, ecological momentary assessment, binge eating, purging, dietary restriction, mealtime anxiety, scoping review, physiological stress response

Huntington’s disease is an inherited, progressive brain disorder caused by an expanded CAG repeat in the huntingtin gene. The mutation produces a toxic protein that gradually damages striatal and cortical neurons, giving rise to a characteristic combination of involuntary movements, cognitive decline and psychiatric disturbance. There is currently no therapy that slows the underlying neurodegenerative process; available drugs manage symptoms, chiefly the movement disorder, while the disease continues its course over one to two decades. Against that backdrop, interventions that target the metabolic environment of vulnerable neurons have attracted growing interest, because mounting evidence suggests that mitochondrial dysfunction and altered energy metabolism are central players in the disease process rather than incidental byproducts of it.

The scientific rationale for testing fasting in Huntington’s disease stretches back more than two decades. In 2003, a team led by Wenzhen Duan reported in the Proceedings of the National Academy of Sciences that dietary restriction normalized glucose metabolism and slowed disease progression in a mouse model of the disorder — the first preclinical demonstration that manipulating meal timing could influence the course of Huntington-like pathology. That observation languished in relative obscurity for years, but it seeded a line of research that matured into a comprehensive review published in Translational Neurodegeneration in 2024, in which R. G. Wells, L. E. Neilson, A. W. McHill and A. L. Hiller synthesized the animal evidence on dietary fasting and time-restricted eating in Huntington’s disease and proposed mechanisms through which periodic metabolic stress might protect the fragile neurons that die first in patients.

Those proposed mechanisms converge on a handful of interconnected pathways. Fasting periods activate cellular stress-response programs, including autophagy, the cellular housekeeping system that clears damaged proteins and organelles — a process of particular relevance in Huntington’s disease, where misfolded mutant huntingtin protein accumulates inside neurons. Fasting also promotes mitochondrial biogenesis and improves metabolic flexibility, the capacity of cells to switch between glucose and fatty-acid fuel sources. Impaired glucose metabolism and mitochondrial dysfunction are well documented in the disease, and studies of patient-derived fibroblasts have shown that lower mitochondrial oxygen consumption is associated with an earlier age of motor onset, independent of CAG repeat size. In other words, the bioenergetic state of a patient’s cells appears to help determine how quickly the disease unfolds, raising the possibility that interventions which improve cellular energy handling could shift that trajectory.

Translating that biology into a human trial required answering a practical question first: can people with early-stage Huntington’s disease actually adhere to a compressed eating window, and is the regimen safe for a patient population that often struggles with weight loss, swallowing difficulties and heightened metabolic demand? Patients with Huntington’s disease frequently become cachectic as the disease advances, so any dietary intervention that risks accelerating weight or muscle loss would be a non-starter. The trial protocol, published in PLoS ONE in 2025 by the same group, was designed explicitly to test feasibility and tolerability alongside exploratory signals of efficacy, using a twelve-week interventional design in twenty participants with early-stage disease.

The results, now summarized in Nature Metabolism as a Research Briefing accompanying the full pilot study by Wells and colleagues, indicate that the intervention was feasible and well tolerated across the study period. Participants restricted their eating to a daily window of six to eight hours — a form of intermittent fasting that does not require caloric counting or outright fasting days, only a consistent daily schedule. That operational simplicity matters for clinical translation, because adherence is the perennial Achilles heel of dietary interventions, and regimens that demand extreme restriction rarely survive contact with real-world patient life. The pilot’s central achievement is demonstrating that a meaningful fasting window can be implemented in this population without evident harm.

Beyond tolerability, the exploratory analyses generated signals that will shape the design of larger trials. The researchers observed improvements in clinical measures, in plasma neurofilament light and in cellular bioenergetics. Neurofilament light is a structural protein released into the cerebrospinal fluid and blood when axons are injured, and it has emerged as one of the most informative fluid biomarkers of neurodegeneration across a range of disorders. A five-year longitudinal study published in eBioMedicine in 2024 by G. M. Parkin, E. A. Thomas and J. Corey-Bloom mapped the expected annual rise in plasma neurofilament light across the Huntington’s disease spectrum, providing the reference framework against which the changes observed in the fasting pilot can be interpreted. A biomarker trajectory that bends away from the expected rise over twelve weeks is not proof of neuroprotection, but it is exactly the kind of signal that justifies investing in a definitive trial.

The bioenergetics findings connect the human results back to the mechanistic work in cells and animals. Because mitochondrial respiratory capacity in patient cells has been linked to disease onset and progression, measuring cellular energy metabolism before and after the intervention offers a way to ask whether time-restricted eating changes the fundamental metabolic physiology that theory says it should. The pilot’s exploratory improvements in this domain suggest that the intervention engaged the biology it was designed to target, rather than merely changing eating schedules. Body composition and clinical measures were also tracked, addressing the critical safety question of whether compressed eating windows exacerbate the weight loss that plagues many patients — and the reported tolerability indicates the regimen did not produce overt deterioration over the study period.

Caution remains essential at this stage. A pilot study with twenty participants, no control group described in the available summary and exploratory rather than pre-specified confirmatory analyses cannot establish efficacy, and biomarker fluctuations over twelve weeks can reflect measurement variability, seasonal effects or regression to the mean as easily as biological change. The appropriate reading of the work is as a proof of feasibility and signal generation: the study establishes that the intervention can be delivered, that it appears safe in the short term and that its hypothesized targets — neurodegeneration biomarkers and cellular energy metabolism — move in a direction consistent with benefit. Definitive claims will require randomized, controlled trials with larger cohorts, longer follow-up and adequate statistical power, ideally stratified by disease stage and CAG repeat length.

Even so, the significance of the work extends beyond Huntington’s disease. It represents a template for how metabolic interventions long confined to animal models and healthy-volunteer studies can be brought to neurodegenerative populations with careful attention to their specific vulnerabilities. Fasting-based approaches are being explored in Parkinson’s disease, multiple sclerosis and other neurological conditions, and the Huntington’s pilot provides one of the first direct human data points in a monogenic neurodegenerative disorder, where biomarkers are unusually well characterized and disease progression can be tracked with precision. If larger trials confirm that something as simple as when patients eat — independent of what or how much — can alter the trajectory of a fatal genetic brain disease, the implications for how medicine thinks about meal timing would be profound. For now, the message to patients is one of tempered optimism: the evidence is early, the trials are small, and no one should undertake extended fasting without medical supervision. But the door that Duan’s mice opened in 2003 has now been walked through by human patients, and the field will be watching closely to see what lies on the other side.

Subject of Research: Clinical testing of time-restricted eating as an intermittent fasting intervention in early-stage Huntington's disease

Article Title: Meal timing as medicine: clinical evidence for intermittent fasting in Huntington’s disease

Article References: Meal timing as medicine: clinical evidence for intermittent fasting in Huntington’s disease. (2026). Nature Metabolism. https://doi.org/10.1038/s42255-026-01613-w

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01613-w

Keywords: Huntington's disease, time-restricted eating, intermittent fasting, neurofilament light, mitochondrial bioenergetics, neurodegeneration, pilot study, metabolism, clinical trial, dietary restriction, Nature Metabolism, biomarkers